Rchr
J-GLOBAL ID：200901016371476131   Update date: Oct. 31, 2024

Kamada Haruhiko

カマダ ハルヒコ | Kamada Haruhiko
Affiliation and department：
National Institutes of Biomedical Innovation, Health and Nutrition

About National Institutes of Biomedical Innovation, Health and Nutrition


Job title： Project Leader
Other affiliations (4)：
  • 国立研究開発法人医薬基盤・健康・研究所  創薬資源研究支援センター 疾患モデル小動物研究室   室長
  • Kyoto University  Graduate School of Pharmaceutical Sciences 
  • Osaka University  Graduate School of Pharmaceutical Sciences 
  • Osaka University
Homepage URL  (1)： http://www.nibiohn.go.jp/bio-r/index.htm
Research field  (7)： Tumor diagnostics and therapeutics ,  Clinical pharmacy ,  Hematology and oncology ,  Structural biochemistry ,  Pathobiochemistry ,  Pharmaceuticals - chemistry and drug development ,  Molecular biology
Research keywords  (14)： 抗体 ,  分子病態学 ,  炎症 ,  腫瘍壊死因子 ,  疾患関連タンパク質 ,  プロテオーム ,  ファージ表面提示法 ,  バイオマーカー ,  血管内皮細胞 ,  炎症性メディエーター ,  炎症性たんぱく質 ,  乳がん ,  プロテオミクス ,  血液学(血栓止血)
Research theme for competitive and other funds  (39)：
  • 2024 - 2028 Efficient Drug Targeting by oncolytic virus-meidated tumor-specific expression of artificial receptors
  • 2022 - 2025 Development of antibody design optimized for active targeting
  • 2022 - 2024 <混ぜる>抗体工学 ~二重特異性抗体の効率的な創出法の開発~
  • 2021 - 2024 機能性食品成分の腸管における標的分子の同定と腸内細菌叢への作用の解析
  • 2020 - 2024 ヒトウテログロビン蛋白質を利用した低分子化二重特異性抗体の構築
Show all
Papers (173)：
  • Manami Kodaka, Akito Kikuchi, Kotaro Kawahira, Haruhiko Kamada, Ryo Katsuta, Ken Ishigami, Tsukasa Suzuki, Yuji Yamamoto, Jun Inoue. Identification of a novel target of sulforaphane: Sulforaphane binds to acyl-protein thioesterase 2 (APT2) and attenuates its palmitoylation. Biochemical and Biophysical Research Communications. 2024
  • Hiroki Akiba, Tomoko Ise, Reiko Satoh, Yasuhiro Abe, Kouhei Tsumoto, Hiroaki Ohno, Haruhiko Kamada, Satoshi Nagata. Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule. 2024
  • Takashi Osawa, Ryosuke Kita, Yuuya Kasahara, Harumi Yamaguma, Taisuke Nakayama, Haruhiko Kamada, Satoshi Obika. In vitro screening of chemically synthesized dipeptide-antisense oligonucleotide conjugates to identify ligand molecules enhancing their activity. Bioorganic & Medicinal Chemistry. 2024. 110. 117814-117814
  • Yoji Tsugawa, Kentaro Furukawa, Tomoko Ise, Masahiro Takayama, Takeshi Ota, Takayuki Kuroda, Shinya Shano, Takashi Hashimoto, Haruyo Konishi, Takeshi Ishihara, et al. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo. 2024
  • Masaki Inoue, Yuta Tsuji, Ayaka Kashiwada, Asahi Yokoyama, Akane Iwata, Yasuhiro Abe, Haruhiko Kamada, Shin-ichi Tsunoda. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering. Biochemical and Biophysical Research Communications. 2024
ｍore...
MISC (192)：
  • Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, Jianbo An, Daichi Utsumi, Satoshi Nagata, Haruhiko Kamada, et al. Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2022. 95. 2-O
  • Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, Yoshihiro Kawaoka, Keiji Kuba, Yasuhiro Yasutomi. Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2022. 95. 2-P
  • 田中佑弥, 谷奥有里花, 阿曽古都美, 中山泰亮, 鎌田春彦, 山口卓男, 小比賀聡. Synthesis and evaluation of lipid-modified antisense oligonucleotides. 日本薬学会年会要旨集(Web). 2021. 141st
  • Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, Masaki Imai, Saori Takahashi, Daichi Utsumi, Jianbo An, et al. Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2021. 94. 2-P2
  • 東阪和馬, 東阪和馬, 大須賀絵理, 笠原淳平, 豊田麻人, 尾花理徳, 鎌田春彦, 前田真貴子, 長野一也, 藤尾慈, et al. 心分泌蛋白質に着目した心不全に対する新規バイオマーカー探索. 日本薬学会年会要旨集(CD-ROM). 2018. 138th. 4. ROMBUNNO.27G-pm06-61
ｍore...
Books (1)：
  • 図説分子病態学
    中外医学社 2008
Education (4)：
  • - 2000 Osaka University
  • - 2000 Osaka University Graduate School, Division of Pharmaceutical Sciences
  • - 1995 Osaka University School of Pharmaceutical Sciences
  • - 1995 Osaka University Faculty of Pharmaceutical Science
Professional career (1)：
  • PhD (Osaka University)
Work history (9)：
  • 2016 - 現在 National Institutes of Biomedical Innovation, Health and Nutrition CDDR Project Leader
  • 2010 - 2016 National Institutes of Biomedical Innovation, Health and Nutrition
  • 2005 - 2010 National Institutes of Biomedical Innovation, Health and Nutrition
  • 2007 - 2008 Swiss Federal Institute of Technology Guest Researcher
  • 2004 - 2005 国立医薬品食品衛生研究所 大阪支所 主任研究官
Show all
Committee career (1)：
  • 2003 - 日本血栓止血学会 小委員会 動物モデル
Awards (4)：
  • 2019/02 - Osaka Bio Headquater Grand prize Functional antibody creation technology for development of antibody drug
  • 2011/07 - International Society of Thrombosis and Hemostasis Asian-Pacific Scholarship Creation of TNFR1-selective mutant TNF with antagonistic activity.
  • 2006 - 武田科学振興財団 薬学系研究奨励
  • 1998 - 日本薬剤学会優秀論文賞
Association Membership(s) (6)：
THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER ,  日本DDS学会 ,  日本プロテオーム機構 ,  日本薬学会 ,  日本生化学会 ,  日本癌学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM